Leukemia Therapeutics Market Size, Growth

Leukemia Therapeutics Market Research, 2030

Leukemia Therapeutics Market to surpass USD 33.5 billion by 2032 from USD 15.13 billion in 2021 at a CAGR of 7.5% throughout the forecast period 2022-32

Leukemia Therapeutics is the treatment for leukemia depending on the leukemia type the patient has, his age, and his overall health. Moreover, if leukemia has already spread to other tissues or organs of the patient, he needs a different kind of treatment. The main treatment for leukemia is chemotherapy. Chemicals are used in this medication to kill leukemia cells. A single medication or a combination of medications may be given to the patient, depending on the type of leukemia he has. These medications can be taken as pills or they can be injected right into a vein. Other treatment options include Immunotherapy, Targeted Therapy, Radiation Therapy, Bone Marrow Transplant or Stem Cell, and Chimeric Antigen Receptor (CAR) T-cell Therapy.

Market Highlights

The Leukemia Therapeutics Market is expected to project a notable CAGR of 7.5% in 2032.

Leukemia Therapeutics Market to surpass USD 33.5 billion by 2032 from USD 15.13 billion in 2021 at a CAGR of 7.5% in the coming years, i.e., 2022-32. Over the forecast period, the Leukemia Therapeutics Market is projected to be driven by the global introduction of novel therapies and highly promising pipeline medications supported by the rise in leukemia cases. Multiple therapy options and family history of leukemia therapies will also pave the path for the growth of the Leukemia Therapeutics Market.

Figure - Market Analysis of Leukemia Therapeutics Market Analysis of Market

Get More Information - Download Free Sample

Leukemia Therapeutics Market: Segments

The Chronic Lymphocytic segment is expected to grow with a higher CAGR during 2022-32

Leukemia Therapeutics Market is categorized on the basis of Type into Chronic Myeloid, Chronic Lymphocytic, Acute Lymphocytic, Acute Myeloid, and Others. In 2019 the Chronic Lymphocytic segment dominated the market, and it is anticipated to continue during the forecast period. Statistics reveal that compared to alternative treatment options, Chronic Lymphocytic has a higher likelihood of survival. Due to its large patient base and rising treatment demand, the Chronic Myeloid segment currently holds a dominant position in the market.

The Chemotherapy segment is expected to grow with a higher CAGR during 2022-32

Leukemia Therapeutics Market is categorized on the basis of Treatment Type into Chemotherapy, Targeted Therapy, Immunotherapy, and Others. Since chemotherapy is the first line of treatment for leukemia and results in successful treatment outcomes for the patient, the segment is expected to dominate the market throughout the projected period.

Figure - Market Analysis of Global Leukemia Therapeutics Market Analysis of Market

Get More Information - Download Free Sample

Market Dynamics

Growth Drivers

The Growing Cases of Leukemia Worldwide is Majorly Driving the Market

The rising incidence of leukemia around the world is one of the main factors influencing the global Leukemia Therapeutics Market. This is significantly increasing the demand for leukemia treatments. Globally, almost all forms of leukemia, including ALL and CML, are becoming more common. In 2020, the International Agency for Research on Cancer predicted that there will be roughly 474,519 new cases of leukemia worldwide. The increase in patient populations globally is expected to accelerate the Leukemia Therapeutics Market.

Technological Developments and Growing Research and Development Activities

The market is also projected to be driven by expanding R&D efforts and technological advancements, which will have an impact on how the Leukemia Therapeutics Market expands throughout the forecast period. Bone marrow testing, platelet counts, and WBC (white blood cell) differential counts can all be used to detect leukemia. Blood transfusions, bone marrow transplants, immunotherapy, radiation therapy, and chemotherapy are all options for treating leukemia. Thus, the quantity of Leukemia treatments is majorly propelling the market.

Restraint

Side-Effects of the Treatment Products is Hampering the Market Growth

Despite the benefits of leukemia treatment products, unwanted side-effects and reactions are anticipated to restrain the growth of the global Leukemia Therapeutics Market. The negative effects of different therapies can vary, for example, chemotherapy can cause infections, hair loss, high blood pressure, skin issues, fatigue, and other unwanted effects. Similar negative side effects to targeted therapy include liver issues, nausea, hair color loss, diarrhea, and vomiting. The use of leukemia therapeutic items may also be constrained by the fact that some side effects are also associated with some other treatment modalities, such as radiotherapy.

Recent Developments

Sumitomo Dainippon Pharma Oncology, Inc., in March 2022, dosed patients with relapsed or resistant acute myeloid leukemia (AML) or acute lymphocytic leukemia in the Phase 1/2 study of DSP-5336, an inhibitor of melanin binding to mixed-lineage leukemia (MLL) protein (ALL).
Bristol-Myers Squibb declared in April 2021 that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended clearance for their medication Onureg for Oral Maintenance Therapy for the treatment of individuals with acute myeloid leukemia.
The U.S. FDA approved Venclexta combinations, a medicine from F. Hoffmann-La Roche Ltd., in October 2020 for the treatment of people with acute myeloid leukemia.

Leukemia Therapeutics Market: Key Players

Johnson & Johnson

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

Novartis
Hoffmann-La Roche
Sanofi
GlaxoSmithKline Plc
Pfizer
AbbVie
Novartis Pharmaceuticals
Takeda Pharmaceutical
Bristol-Myers Squibb
Amgen
Daiichi Sankyo
Gilead Sciences
Eisai C.
Incyte Corp
Other Prominent Players

Leukemia Therapeutics Market: Regions

Leukemia Therapeutics Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America registered a major market share in 2019. The region's dominance is attributed to factors like high healthcare spending, the presence of numerous key players involved in the development of leukemia products, and the rising prevalence of leukemia cases throughout North America.

Asia Pacific is predicted to have a higher CAGR during the forecast period due to the increased incidence of cancer. The region's leukemia markets are anticipated to expand most quickly in China and India. Increasing R&D spending, a huge patient base, and expanding government financing are some of the main factors propelling the Leukemia Therapeutics Market in emerging nations.

Get More Information - Download Free Sample

Leukemia Therapeutics Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Leukemia Therapeutics Market report also contains analysis on:

Leukemia Therapeutics Market Segments:

By Type
- Chronic Myeloid
- Chronic Lymphocytic
- Acute Lymphocytic
- Acute Myeloid
- Others
By Route of Administration
- Oral
- Injectable
By Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Leukemia Therapeutics Market Dynamics
Leukemia Therapeutics Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Leukemia Therapeutics Market Report Scope and Segmentation

REPORT ATTRIBUTE	DETAILS
Market Size Value in 2021	USD 15.13 billion
Revenue Forecast in 2032	USD 33.5 billion
Growth Rate	CAGR of 7.5% from 2022 to 2032
Base Year for Estimation	2021
Quantitative Units	Revenue in USD billion and CAGR from 2022 to 2032
Report Coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered	Type, Route of Administration, Treatment Type, and Region
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Key Companies Profiled	Johnson & Johnson, Novartis, Hoffmann-La Roche, Sanofi, GlaxoSmithKline Plc, Pfizer, AbbVie, Novartis Pharmaceuticals, Takeda Pharmaceutical, Bristol-Myers Squibb, Amgen, Daiichi Sankyo, Gilead Sciences, Eisai C., Incyte Corp, and Other Prominent Players.

Frequently Asked Questions (FAQ):

The Leukemia Therapeutics Market size was estimated at USD 15.13 billion in 2021 and is expected to reach USD 33.5 billion in 2032.

Leukemia Therapeutics is the treatment for leukemia depending on the leukemia type the patient has, his age, and his overall health.

The Chronic Lymphocytic and Chemotherapy segments accounted for the larger share of the Leukemia Therapeutics Market.

Key players in the Leukemia Therapeutics Market are Johnson & Johnson, Novartis, Hoffmann-La Roche, Sanofi, GlaxoSmithKline Plc, Pfizer, AbbVie, Novartis Pharmaceuticals, Takeda Pharmaceutical, Bristol-Myers Squibb, Amgen, Daiichi Sankyo, Gilead Sciences, Eisai C., Incyte Corp, and Other Prominent Players.

The Leukemia Therapeutics Market is majorly driven by the global introduction of novel therapies and highly promising pipeline medications supported by the rise in leukemia cases.